Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy

Kyle B. Lupo, Sandro Matosevic

Cancers · 2019 · Review · CC BY

doi:10.3390/cancers11060769 (opens in a new tab)

Abstract

Natural killer (NK) cells are attractive within adoptive transfer settings in cancer immunotherapy due to their potential for allogeneic use; their alloreactivity is enhanced under conditions of killer immunoglobulin-like receptor (KIR) mismatch with human leukocyte antigen (HLA) ligands on cancer cells. In addition to this, NK cells are platforms for genetic modification, and proliferate in vivo for a shorter time relative to T cells, limiting off-target activation. Current clinical studies have demonstrated the safety and efficacy of allogeneic NK cell adoptive transfer therapies as a means for treatment of hematologic malignancies and, to a lesser extent, solid tumors. However, challenges associated with sourcing allogeneic NK cells have given rise to controversy over the contribution of NK cells to graft-versus-host disease (GvHD). Specifically, blood-derived NK cell infusions contain contaminating T cells, whose activation with NK-stimulating cytokines has been known to lead to heightened release of proinflammatory cytokines and trigger the onset of GvHD in vivo. NK cells sourced from cell lines and stem cells lack contaminating T cells, but can also lack many phenotypic characteristics of mature NK cells. Here, we discuss the available published evidence for the varying roles of NK cells in GvHD and, more broadly, their use in allogeneic adoptive transfer settings to treat various cancers.

References 182

  1. 1.
    The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments · 2017
    No notice
  2. 2.

    Pegram H.J., Andrews D.M., Smyth M.J., Darcy P.K., Kershaw M.H. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 2011;89:216-224.

    Not in our library10.1038/icb.2010.78 (opens in a new tab)

  3. 3.

    Thielens A., Vivier E., Romagné F. NK cell MHC class I specific receptors (KIR): From biology to clinical intervention. Curr. Opin. Immunol. 2012;24:239-245.

    Not in our library10.1016/j.coi.2012.01.001 (opens in a new tab)

  4. 4.

    Geller M.A., Miller J.S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011;3:1445-1459.

    Not in our library10.2217/imt.11.131 (opens in a new tab)

  5. 5.

    Farnault L., Sanchez C., Baier C., Le Treut T., Costello R.T. Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. Clin. Dev. Immunol. 2012;2012:421702.

    Not in our library10.1155/2012/421702 (opens in a new tab)

  6. 6.

    Pende D., Marcenaro S., Falco M., Martini S., Bernardo M.E., Montagna D., Romeo E., Cognet C., Martinetti M., Maccario R., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113:3119-3129.

    Not in our library10.1182/blood-2008-06-164103 (opens in a new tab)

  7. 7.

    Davis Z.B., Felices M., Verneris M.R., Miller J.S. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015;21:486-491.

    Not in our library10.1097/ppo.0000000000000156 (opens in a new tab)

  8. 8.

    Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 1978;148:1687-1698.

    Not in our library10.1084/jem.148.6.1687 (opens in a new tab)

  9. 9.

    Gill S., Olson J.A., Negrin R.S. Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor, and Graft-versus-Host Responses. Biol. Blood Marrow Transplant. 2009;15:765-776.

    Not in our library10.1016/j.bbmt.2009.01.019 (opens in a new tab)

  10. 10.

    Carayol G., Robin C., Bourhis J.-H., Bennaceur-Griscelli A., Chouaib S., Coulombel L., Caignard A. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur. J. Immunol. 1998;28:1991-2002.

    Not in our library10.1002/(sici)1521-4141(199806)28:06<1991::aid-immu1991>3.0.co;2-7 (opens in a new tab)

  11. 11.

    Noval Rivas M., Hazzan M., Weatherly K., Gaudray F., Salmon I., Braun M.Y. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J. Immunol. 2010;184:6790-6798.

    Not in our library10.4049/jimmunol.0902598 (opens in a new tab)

  12. 12.

    Asai O., Longo D.L., Tian Z.G., Hornung R.L., Taub D.D., Ruscetti F.W., Murphy W.J. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Investig. 1998;101:1835-1842.

    Not in our library10.1172/jci1268 (opens in a new tab)

  13. 13.

    Olson J.A., Leveson-Gower D.B., Gill S., Baker J., Beilhack A., Negrin R.S. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293-4301.

    Not in our library10.1182/blood-2009-05-222190 (opens in a new tab)

  14. 14.

    Xun C., Brown S.A., Jennings C.D., Henslee-Downey P.J., Thompson J.S. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56:409-417.

    Not in our library10.1097/00007890-199308000-00031 (opens in a new tab)

  15. 15.

    Cooley S., McCullar V., Wangen R., Bergemann T.L., Spellman S., Weisdorf D.J., Miller J.S. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106:4370-4376.

    Not in our library10.1182/blood-2005-04-1644 (opens in a new tab)

  16. 16.

    Xun C.Q., Thompson J.S., Jennings C.D., Brown S.A. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Transplantation. 1995;60:821-827.

    Not in our library10.1097/00007890-199510000-00011 (opens in a new tab)

  17. 17.

    Long E.O., Kim H.S., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013;31:227-258.

    Not in our library10.1146/annurev-immunol-020711-075005 (opens in a new tab)

  18. 18.

    Konjević G., Vuletić A., Džodić K.M.M., Radan D. The Role of Activating and Inhibitory NK Cell Receptors in Antitumor Immune Response. Nat. Killer Cells. 2017.

    Not in our library10.5772/intechopen.69729 (opens in a new tab)

  19. 19.

    Almeida C.R., Davis D.M. Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density. J. Immunol. 2006;177:6904-6910.

    Not in our library10.4049/jimmunol.177.10.6904 (opens in a new tab)

  20. 20.

    Kumar V., McNerney M.E. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 2005;5:363-374.

    Not in our library10.1038/nri1603 (opens in a new tab)

  21. 21.

    Muntasell A., Ochoa M.C., Cordeiro L., Berraondo P., López-Díaz de Cerio A., Cabo M., López-Botet M., Melero I. Targeting NK-cell checkpoints for cancer immunotherapy. Curr. Opin. Immunol. 2017;45:73-81.

    Not in our library10.1016/j.coi.2017.01.003 (opens in a new tab)

  22. 22.

    Orange J.S. Formation and function of the lytic NK-cell immunological synapse. Nat. Rev. Immunol. 2008;8:713-725.

    Not in our library10.1038/nri2381 (opens in a new tab)

  23. 23.

    Binstadt B.A., Brumbaugh K.M., Dick C.J., Scharenberg A.M., Williams B.L., Colonna M., Lanier L.L., Kinet J.P., Abraham R.T., Leibson P.J. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity. 1996;5:629-638.

    Not in our library10.1016/s1074-7613(00)80276-9 (opens in a new tab)

  24. 24.

    Davis D.M., Chiu I., Fassett M., Cohen G.B., Mandelboim O., Strominger J.L. The human natural killer cell immune synapse. Proc. Natl. Acad. Sci. USA. 1999;96:15062-15067.

    Not in our library10.1073/pnas.96.26.15062 (opens in a new tab)

  25. 25.

    Viant C., Fenis A., Chicanne G., Payrastre B., Ugolini S., Vivier E. SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat. Commun. 2014;5:5108.

    Not in our library10.1038/ncomms6108 (opens in a new tab)

  26. 26.

    Yusa S.-I., Campbell K.S. Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells. J. Immunol. 2003;170:4539-4547.

    Not in our library10.4049/jimmunol.170.9.4539 (opens in a new tab)

  27. 27.

    Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154:383-393.

    Not in our library10.1111/imm.12921 (opens in a new tab)

  28. 28.

    Vyas Y.M., Mehta K.M., Morgan M., Maniar H., Butros L., Jung S., Burkhardt J.K., Dupont B. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J. Immunol. 2001;167:4358-4367.

    Not in our library10.4049/jimmunol.167.8.4358 (opens in a new tab)

  29. 29.

    Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005;23:225-274.

    Not in our library10.1146/annurev.immunol.23.021704.115526 (opens in a new tab)

  30. 30.

    Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008;9:503-510.

    Not in our library10.1038/ni1582 (opens in a new tab)

  31. 31.

    Shifrin N., Raulet D.H., Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin. Immunol. 2014;26:138-144.

    Not in our library10.1016/j.smim.2014.02.007 (opens in a new tab)

  32. 32.

    Boudreau J.E., Hsu K.C. Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol. 2018;39:222-239.

    Not in our library10.1016/j.it.2017.12.001 (opens in a new tab)

  33. 33.
    Remodeling of secretory lysosomes during education tunes functional potential in NK cells · 2019
    No notice
  34. 34.
    Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors · 2019
    No notice
  35. 35.

    Chambers A.M., Lupo K.B., Matosevic S. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells. Front. Immunol. 2018;9:2517.

    Not in our library10.3389/fimmu.2018.02517 (opens in a new tab)

  36. 36.

    Dao T.N., Matosevic S. Immunometabolic Responses of Natural Killer Cells to Inhibitory Tumor Microenvironment Checkpoints. Immunometabolism. 2019;1:e190003.

    Not in our library

  37. 37.

    Cantoni C., Huergo-Zapico L., Parodi M., Pedrazzi M., Mingari M.C., Moretta A., Sparatore B., Gonzalez S., Olive D., Bottino C., et al. NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J. Immunol. Res. 2016;2016:4684268.

    Not in our library10.1155/2016/4684268 (opens in a new tab)

  38. 38.

    Remark R., Alifano M., Cremer I., Lupo A., Dieu-Nosjean M.-C., Riquet M., Crozet L., Ouakrim H., Goc J., Cazes A., et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin. Cancer Res. 2013;19:4079-4091.

    Not in our library10.1158/1078-0432.ccr-12-3847 (opens in a new tab)

  39. 39.

    Habif G., Crinier A., André P., Vivier E., Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell. Mol. Immunol. 2019;16:415.

    Not in our library10.1038/s41423-019-0224-2 (opens in a new tab)

  40. 40.

    Matosevic S. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. J. Immunol. Res. 2018;2018:4054815.

    Not in our library10.1155/2018/4054815 (opens in a new tab)

All 182 references

Cited by papers we hold 9

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.